@article{12dbe0c85ffa462f931233e85b02b7e8,
title = "Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)",
keywords = "HER2-positive, dual HER2 blockade, First line, Metastatic breast cancer, Paclitaxel, Pertuzumab",
author = "\{PERUSE investigators\} and T. Bachelot and E. Ciruelos and A. Schneeweiss and F. Puglisi and T. Peretz-Yablonski and I. Bondarenko and S. Paluch-Shimon and A. Wardley and Merot, \{J. -L.\} and \{du Toit\}, Y. and V. Easton and N. Lindegger and D. Miles and Kamel Bouzid and Mario Campone and Bruno Coudert and Zbigniew Nowecki and Hassan Errihani and Florence Dalenc and Ana Ferreira and Max Mano and Francesco Ricci and Haralabos Kalofonos and Claudia Andreetta and Filippo Montemurro and Sophie Barrett and Qingyuan Zhang and Dimitris Mavroudis and Juan Matus and Carlos Beato and Xichun Hu and Rabab Gaafar and Azeem, \{Hamdy Abdel\} and Christophe Perrin and Johannes Ettl and Istvan Lang and Sunil Verma and Huiping Li and Etienne Brain and Oliver Hoffmann and Anna Cariello and Carlo Tondini and Taher Altwegeiri and Niklas Loman and Michael Lux and Antonio Frassoldati and Zeba Aziz and Fernando Salas and Joanna Streb and Sercan Aksoy",
year = "2019",
month = may,
doi = "10.1093/annonc/mdz061",
language = "English",
volume = "30",
pages = "766--773",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Ltd",
number = "5",
}
SKH 3 Sağlık ve Kaliteli Yaşam